Arkolith/Insider Trading/KNSA/Form 4

Ragosa Mark

CHIEF FINANCIAL OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Nov 14, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$815K
Net Open-Market Flow
-$815K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 12, 2025Option exercise(M)20K$30.93$616K51K
Nov 12, 2025Sell(S)20K$40.94$815K31K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 12, 2025Option exercise(M)20K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001835458-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML